Skip to main content
PMC home page
American Journal of Alzheimer's Disease and Other Dementias logoLink to American Journal of Alzheimer's Disease and Other Dementias
. 2002 Jan-Feb;17(1):23–29. doi: 10.1177/153331750201700104

Cognitive impairments in multiple sclerosis: A review

Eduardo Adonias DeSousa 1, Ross H Albert 2, Bernadette Kalman 3
PMCID: PMC10833971  PMID: 11831417

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Cognitive impairment (CI) may develop at any time during the course of the disease in the presence or absence of neurological disability. On the basis of comprehensive neuropsychological studies, there is now a consensus among investigators that 45 percent to 65 percent of MS patients suffer from some degree and form of cognitive difficulty. Features of CI include bradyphrenia; impaired attention, concentration and abstract reasoning; reduced manual speed and dexterity; deficits in memory retrieval; and language deficits in both the relapsingremitting and progressive forms of MS. Impairments in all cognitive domains may result from the diffuse spread of microscopic pathology, although a preferential lobar distribution of plaques can present with a predominant deficit in the corresponding cognitive function. Nevertheless, the severity of CI best correlates with total microscopic and macroscopic disease burden of the brain as defined by recently developed magnetic resonance imaging (MRI) sequences. A disruption of connecting intercortical and subcortical pathways is likely to be the main cause of metabolic and functional abnormalities in neurons. However, a direct toxic effect of soluble inflammatory products may also compromise neuronal function and survival. Early treatment of MS with interferons and copaxone can prevent or delay the onset of both neurological and cognitive disabilities by reducing the inflammatory activity and damage in the CNS. Until more powerful neuroprotective agents become available, simple neuropsychological screening and cognitive rehabilitation for memory and language impairments will remain important components in the care of MS patients.

Keywords: multiple sclerosis, cognitive impairments, neuropathology, neuroimaging

Full Text

The Full Text of this article is available as a PDF (90.3 KB).

Contributor Information

Eduardo Adonias DeSousa, Department of Neurology, MCP Hahnemann University, Philadelphia, Pennsylvania..

Ross H. Albert, Department of Biochemistry, MCP Hahnemann University, Philadelphia, Pennsylvania..

Bernadette Kalman, Department of Neurology, MCP Hahnemann University, Philadelphia, Pennsylvania..

References

  1. Beatty WW, Paul RH, Wilbanks SL, et al.: Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology. 1995; 45: 718-723. [DOI] [PubMed] [Google Scholar]
  2. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. 1996; 46: 907-911. [DOI] [PubMed] [Google Scholar]
  3. Bakshi R, Ariyatana S, Benedict RHB, Jacobs L: Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol. 2001; 58: 742-748. [DOI] [PubMed] [Google Scholar]
  4. Lazeron RH, Langdon DW, Filippi M, et al.: Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. Multiple Sclerosis. 2000; 6: 280-285. [DOI] [PubMed] [Google Scholar]
  5. Patti F, DiStefano M, DePascalis D, et al.: May there exist specific MRI findings predictive of dementia in multiple sclerosis patients? Functional Neurol. 1995; 10: 83-90. [PubMed] [Google Scholar]
  6. Rovaris M, Filippi M, Falautano M, et al.: Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology. 1998; 50: 1601-1608. [DOI] [PubMed] [Google Scholar]
  7. Cercignani M, Iannucci G, Rocca MA, et al.: Pathological damage in MS assessed by diffusion-weighted and magnetization transfer MRI. Neurology. 2000; 54: 1139-1144. [DOI] [PubMed] [Google Scholar]
  8. VanWalderveen MA, Barkfof F, Pouwels PJ, et al.: Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol. 1999; 46: 79-87. [DOI] [PubMed] [Google Scholar]
  9. Goodkin DE, Rooney WD, Sloan R, et al.: A serial study of new lesions and the white matter from which they arise. Neurology. 1998; 51: 1689-1697. [DOI] [PubMed] [Google Scholar]
  10. Filippi M, Tortorella C, Rovaris M, et al.: Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg & Psych. 2000; 68: 157-161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fu L, Matthews PM, DeStefano N, et al.: Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain. 1998; 121: 103-113. [DOI] [PubMed] [Google Scholar]
  12. Davie CA, Silver NC, Barker GJ, et al.: Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg & Psych. 1999; 67: 710-715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kalman B, Lublin FD: Spectrum and classification of inflammatory demyelinating diseases of the central nervous system. Curr Neurol Neurosci. 2001; 1: 249-256. [DOI] [PubMed] [Google Scholar]
  14. Chataway J, Feakes R, Coraddu F, et al.: The genetics of multiple sclerosis: Principles, background and updated results of the United Kingdom systematic genome screen. Brain. 1998; 121: 1869-1887. [DOI] [PubMed] [Google Scholar]
  15. Lucchinetti C, Bruck W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: implication for the pathogenesis of demyelination. Ann Neurol. 2000; 47: 707-717. [DOI] [PubMed] [Google Scholar]
  16. Peterson JW, Chang A, Trapp B: Demyelinated lesions in the cerebral cortex of MS patients contain transected dendrites, transected axons, and apoptotic neurons. Neurology. 2001; (Suppl 3): A96-A96. [Google Scholar]
  17. Rao SM, Leo GJ, Bernardin L, Unverzagt F: Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology. 1991; 41: 685-191. [DOI] [PubMed] [Google Scholar]
  18. McIntosh-Michaelis SA, Roberts MH, Wilkinson SM, et al.: The prevalence of cognitive impairment in a community survey of multiple sclerosis. Br J Med Psych. 1991; 333-348. [DOI] [PubMed] [Google Scholar]
  19. LaRocca NG: Cognitive and emotional disorders. In Burks JS, Johnson KP (eds.): Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. New York: Demos, 2000: 405-421. [Google Scholar]
  20. Newman JP: Multiple sclerosis (correspondence). NEJM. 2001; 1: 381-382. [Google Scholar]
  21. Bever CT, Grattan L, Panitch HS, Johnson KP: The Brief Repeatable Battery of Neuropsychological Tests for multiple sclerosis: A preliminary serial study. Multiple sclerosis. 1995; 1: 165-169. [DOI] [PubMed] [Google Scholar]
  22. Foong J, Rozewicz L, Quaghebeur G, et al.: Neuropsychological deficits in multiple sclerosis after acute relapse. J Neurol Neurosurg & Psych. 1998; 64: 529-532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kujala P, Portin R, Ruutiainen J: Language functions in incipient cognitive decline in multiple sclerosis. J Neurol Sci. 1996; 141: 79-86. [DOI] [PubMed] [Google Scholar]
  24. Amato MP, Ponziani G, Pracucci G, et al.: Cognitive impairment in early-onset multiple sclerosis: Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol. 1995; 52: 168-172. [DOI] [PubMed] [Google Scholar]
  25. Klonoff H, Clark C, Oger J, et al.: Neuropsychological performance in patients with mild multiple sclerosis. J Nerv Ment Dis. 1991; 179: 127-131. [DOI] [PubMed] [Google Scholar]
  26. Thronton AE, Naftail R. Memory impairment in multiple sclerosis: A quantitative review. Neuropsychology. 1997; 11: 357-366. [DOI] [PubMed] [Google Scholar]
  27. Schultheis MT, Garay E, DeLuca J: The influence of cognitive impairment on driving performance in multiple sclerosis. Neurology. 2001; 56: 1089-1094. [DOI] [PubMed] [Google Scholar]
  28. Rovaris M, Filippi M, Minicucci L, et al.: Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. Am J Neurorad. 2000; 21: 402-408. [PMC free article] [PubMed] [Google Scholar]
  29. Tsolaki M, Drevelegas A, Karachristianou S, et al.: Correlation of dementia, neuropsychological and MRI findings in multiple sclerosis. Dementia. 1994; 5: 48-52. [DOI] [PubMed] [Google Scholar]
  30. Clark CM, James G, Li D, et al.: Ventricular size, cognitive function and depression in patients with multiple sclerosis. Can J Neurol Sci. 1992; 19: 352-356. [PubMed] [Google Scholar]
  31. Comi G, Filippi M, Martinelli V, et al.: Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. J Neurol Sci. 1993; 115: 566-573. [DOI] [PubMed] [Google Scholar]
  32. Cristodoulou L, Krupp W, Huang D, et al.: Cognitive correlates of quantitative MRI and MR spectroscopy in multiple sclerosis. Neurology. 2001; (Suppl 3): A191-A191. [Google Scholar]
  33. Pozzilli C, Passafiume D, Bernardi S, et al.: SPECT, MRI and cognitive functions in multiple sclerosis. J Neurol Neurosurg & Psych. 1991; 54: 110-115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ryan L, Clark CM, Klonoff H, et al.: Patterns of cognitive impairment in relapsing-remitting multiple sclerosis and their relationship to neuropathology on magnetic resonance images. Neuropsychology. 1996; 10: 176-193. [Google Scholar]
  35. Huber SJ, Paulson GW, Shuttleworth EC, et al.: Magnetic resonance imaging correlates of dementia in multiple sclerosis. Arch Neurol. 1987; 44: 732-736. [DOI] [PubMed] [Google Scholar]
  36. Swirsky-Sacchetti T, Mitchell DR, Seward J, et al.: Neuropsychological and structural brain lesions in multiple sclerosis: a regional analysis. Neurology. 1992; 42: 1291-1295. [DOI] [PubMed] [Google Scholar]
  37. Arnett PA, Rao SM, Bernardin L, et al.: Relationship between frontal lobe lesions and Wisconsin Card Sorting Test performance in patients with multiple sclerosis. Neurology. 1994; 44: 420-425. [DOI] [PubMed] [Google Scholar]
  38. Sperling RA, Guttmann CR, Hohol MJ, et al.: Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: A longitudinal study. Arch Neurol. 2001; 58: 115-121. [DOI] [PubMed] [Google Scholar]
  39. Comi G, Rovaris M, Leocani L, et al.: Assessment of the damage of the cerebral hemispheres in MS using neuroimaging techniques. J Neurol Sci. 2000; 172(Suppl 1): S63-S66. [DOI] [PubMed] [Google Scholar]
  40. van Buchem MA, McGowan JC, Grossman RI: Magnetization transfer histogram methodology: its clinical and neuropsychological correlates. Neurology. 1999; 53(Suppl 3): S23-S28. [PubMed] [Google Scholar]
  41. Nocentini U, Rossini PM, Carlesimo GA, et al.: Patterns of cognitive impairment in secondary progressive stable phase of multiple sclerosis: Correlations with MRI findings. Eur Neurol. 2001; 45: 11-18. [DOI] [PubMed] [Google Scholar]
  42. Jeffrey DR, Absher J, Pfeiffer FE, Jackson H. Cortical deficit in multiple sclerosis on the basis of subcortical lesion. Multiple Sclerosis. 2000; 6: 50-55. [DOI] [PubMed] [Google Scholar]
  43. Sun X, Tanaka M, Kondo S, et al.: Clinical significance of reduced cerebral metabolism in multiple sclerosis: A combined PET and MRI study. Ann Nuclear Med. 1998; 12: 89-94. [DOI] [PubMed] [Google Scholar]
  44. Blinkenberg M, Rune K, Jensen CV, et al.: Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology. 2000; 54: 558-564. [DOI] [PubMed] [Google Scholar]
  45. Joffe RT, Lippert GP, Gray TA, et al.: Mood disorder and multiple sclerosis. Arch Neurol. 1987; 44: 376-378. [DOI] [PubMed] [Google Scholar]
  46. Sadovnick AD, Eisen K, Ebers GC, et al.: Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991; 41: 1193-1196. [DOI] [PubMed] [Google Scholar]
  47. Zorzon M, Zivadinov R, Ukmar M, et al.: A two-year follow-up study of MRI changes and depression in 95 patients with multiple sclerosis. Neurology. 2001; (Suppl 3): A256-A256. [Google Scholar]
  48. Krupp LB, Sliwinski M, Masur DM, et al.: Cognitive functioning and depression in patients with chronic fatigue syndrome and multiple sclerosis. Arch Neurol. 1994; 51: 705-710. [DOI] [PubMed] [Google Scholar]
  49. Moller A, Wiedemann G, Rohde U, et al.: Correlation of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psych Scand. 1994; 89: 117-121. [DOI] [PubMed] [Google Scholar]
  50. Comi G, Filippi M, Martinelli V, et al.: Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci. 1995; 132: 222-227. [DOI] [PubMed] [Google Scholar]
  51. Rudick R, Antel J, Confavreux C, et al.: Recommendation from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997; 42: 379-382. [DOI] [PubMed] [Google Scholar]
  52. Ebers GC, Kukay K, Bulman DE. et al.: A full genome search in multiple sclerosis. Nature Genetics. 1996; 13: 472-476. [DOI] [PubMed] [Google Scholar]
  53. Sawcer S, Jones HB, Feakes R et al.: A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genetics. 1996; 13: 464-468. [DOI] [PubMed] [Google Scholar]
  54. The Multiple Sclerosis Genetics Group. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nature Genetics. 1996; 13: 469-471. [DOI] [PubMed] [Google Scholar]
  55. Kuokannen S, Gschwend M, Rioux JD, et al.: Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet. 1997; 61: 1379-1387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Hogh P, Oturai A, Schreiber K, et al.Apolipoprotein-E and multiple sclerosis: Impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Multiple Sclerosis. 2000; 6: 226-230. [DOI] [PubMed] [Google Scholar]
  57. Chapman J, Vinokurov S, Achiron A, et al.: ApoE genotype is a major predictor of long-term progression of disability in MS. Neurology. 2001; 56: 312-316. [DOI] [PubMed] [Google Scholar]
  58. Oliveri RL, Citadella R, Sibilia G, et al.: ApoE and risk of cognitive impairment in multiple sclerosis. Acta Neurol Scand. 1999; 100: 290-295. [DOI] [PubMed] [Google Scholar]
  59. IFNB Multiple Sclerosis Study Group: Interferon1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multi-center, randomized, double-blind, placebo-controlled trial. Neurology. 1993; 43: 655-661. [DOI] [PubMed] [Google Scholar]
  60. PRISM (Prevention of Relapses and Disability by Interferonia Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon 1a in relapsing/remitting multiple sclerosis. Lancet. 1998; 352: 1498-1504. [PubMed] [Google Scholar]
  61. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multi-centre randomised trial of interferon 1b in treatment of secondary progressive MS. Lancet. 1998; 352: 1491-1497. [PubMed] [Google Scholar]
  62. Johnson KP, Brooks BR, Cohen JA, et al.: Copolymer 1 reduces exacerbation rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind, placebo-controlled trial. Neurology. 1995; 45: 1268-1276. [DOI] [PubMed] [Google Scholar]
  63. Simon JH, Jacobs LD, Campion MK, et al.: A longitudinal study of brain atrophy in relapsing multiple sclerosis: The multiple sclerosis Collaborative Research Group. Neurology. 1999; 53: 139-148. [DOI] [PubMed] [Google Scholar]
  64. Fischer JS, Priore RG, Jacobs LD, et al.: Neuropsychological effects of Interferon 1a in relapsing-remitting multiple sclerosis. Ann Neurol. 2000; 48: 885-892. [PubMed] [Google Scholar]
  65. Weinstein A, Schwid SI, Schiffer RB, et al.: Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol. 1999; 56: 319-324. [DOI] [PubMed] [Google Scholar]
  66. Selby MJ, Ling N, Williams JM, Dawson A: Interferon 1b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis. Perceptual & Motor Skills. 1998; 86: 1099-1106. [DOI] [PubMed] [Google Scholar]
  67. Smits RC, Emmen HH, Bertelsmann FW, et al.: The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: A pilot study. Neurology. 1994; 44: 1701-1705. [DOI] [PubMed] [Google Scholar]
  68. Greene YM, Tariot PN, Wishart H, et al.: A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharm. 2000; 20: 350-356. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Alzheimer's Disease and Other Dementias are provided here courtesy of SAGE Publications

RESOURCES